Severe exacerbations (requiring ED visits or systemic steroids, or both) Number of people having ≥ 1 exacerbations requiring an ED visit or systemic steroids, or both. Classification varied across studies. Weighted mean study duration: 35 weeks · adults and children with chronic asthma
Macrolides probably leads to lower severe exacerbations (requiring ED visits or systemic steroids, or… compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Macrolide showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
Outcomesa · adults and children with chronic asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severe exacerbations requiring hospitalisation over the study period · adults and children with chronic asthma
Macrolides showed no clear difference in exacerbation requiring hospitalisation Weighted mean study duration:… compared with placebo (moderate certainty).
1 finding from 1 review
Asthma symptoms · adults and children with chronic asthma
1 finding from 1 review
Asthma control · adults and children with chronic asthma
1 finding from 1 review
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · adults and children with chronic asthma
1 finding from 1 review
Use of rescue medication · adults and children with chronic asthma
1 finding from 1 review
FEV1 (L) Weighted mean study duration: 28 weeks · adults and children with chronic asthma
1 finding from 1 review
Serious adverse events (including mortality) · adults and children with chronic asthma
Macrolides showed no clear difference in serious adverse events (including mortality) Weighted mean study… compared with placebo (low certainty).
1 finding from 1 review
Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults with bronchiectasis
Macrolides probably leads to lower ≥ 1 exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with bronchiectasis
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · adults with bronchiectasis
1 finding from 1 review
Change in SGRQ total score · adults with bronchiectasis
1 finding from 1 review
Exacerbation frequency · children with bronchiectasis
Macrolides may leads to lower exacerbation frequency compared with placebo (low certainty).
1 finding from 1 review
Hospitalisation (any cause) · children with bronchiectasis
Macrolides showed no clear difference in hospitalisation: all‐cause compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · children with bronchiectasis
Macrolides showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · children with bronchiectasis
1 finding from 1 review
Quality of life not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found